Vicor Co. (NASDAQ:VICR) VP Kemble D. Morrison sold 5,000 shares of the business’s stock in a transaction on Thursday, May 24th. The stock was sold at an average price of $40.84, for a total transaction of $204,200.00. Following the transaction, the vice president now directly owns 5,000 sh
Of Americans age 50 or older, 47% failed to pass a five-question Social Security quiz, according to a recent MassMutual survey. While this is somewhat better than a previous survey by the same company three years ago that found a 62% failure rate, this is still alarming. After all, Social Securi
China Renaissance, a Beijing investment bank and VC/PE investor, plans to expand its investment funds operations, climbing from $3 billion assets under management currently to $10 billion over the next three years. At the moment, the company runs two funds: Huaxing Growth Capital, focused on technology, media and entertainment, and Huaxing Healthcare. The company plans....More>>>
On Tuesday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biotechnology stock Threshold Pharmaceuticals (NASDAQ: THLD) as a long trade:
The chart below speaks for itself. After trying to work its way above a ceiling at $0.62 for the past several months, that finally happened today, in earnest. Better still, it’s happened after a strong foundation was laid,....More>>>
Shares of Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biotech developing vaccines, have risen about 10.7% as of 3:05 p.m. EDT on Thursday. A positive response to the company’s earnings pushed the stock up a couple days ago, but Thursday’s bump comes in response to recent insider share purchases.
Ligand Pharmaceuticals (NASDAQ:LGND) announced its quarterly earnings results on Tuesday. The biotechnology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.98, Bloomberg Earnings reports. The firm had revenue of $56.16 million during the quarter, compared to analysts’ expectations of $43.02 million. Ligand Pharmaceuticals had a net margin....More>>>
With hundreds of biotech stocks on the market, who can keep up with them all? Probably no one. What happens as a result is that usually only the biggest biotechs (or the small biotechs getting bought by the biggest biotechs) get a lot of coverage.But sometimes those aren’t the stocks to watch most closely.
You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin....More>>>
It has been over two years since I wrote Acceleron Pharma (XLRN) Has Two Potential Blockbusters, so an update is in order. Back then, on July 22, 2015, Acceleron closed at $32.18. It has been very volatile in the meantime, hitting $50.49 on December 29, 2015, but also $21.99 on October 13, 2015. That is part of the thrill (or opportunity, or danger) of investing in clinical-state biotechnology companies.....More>>>
Shares of Dynavax Technologies (DVAX) have fallen by 17% over the past three years. Year-to-date the stock is in the red by around 8% and is also currently our biggest laggard in the Core Biotech model account.
Long time readers are well aware that I believe the best investment ideas have an easily summarized thesis. Here is ours from the Core Biotech series:
Media coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable.....More>>>
Last year, Gilead Sciences (NASDAQ:GILD) managed a feat that very few of its peers ever have (or probably ever will): It shed a staggering $40 billion in value without a single top-selling drug going off patent.
GILD Market Cap data by YCharts.
In fact, the biotech actually launched multiple new products last year, such as the HIV medsOdefsey and Descovy, along with the latest addition....More>>>
Welcome to the third edition in our new series, JF’s Core Biotech Buys.
Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day’s close when an article is published. Depending on the size of a reader’s account, buying or selling in smaller increments may be warranted or....More>>>
SMART Global Holdings(NASDAQ:SGH)stock rose 43.5% in March, according to data provided byS&P Global Market Intelligence.
The stock gains correlated with SMART’s announcement that its executive chairman, Ajay Shah, would become the company’s new CEO, replacing Iain MacKenzie after a transitional period. This was followed by a strong second-quarter earnings....More>>>
Corcept Therapeutics (NASDAQ:CORT) is my favorite type of biotech company. It has an approved, marketed product with ramping sales, promising pipeline candidates, and is beginning to turn a profit. Both guidance by the company and analyst coverage suggest substantial growth in earnings and revenue. While not without the inherent risks of investing in a small/mid-cap biotech companies,....More>>>
Logitech (NASDAQ: LOGI) and TransAct Technologies (NASDAQ:TACT) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings an
Bitcoin was a joyride for early investors, as the cryptocurrency surged from less than $100 earlier in the decade to more than $19,000 last December. However, the digital coin has fallen to around $7,500 since then as the hype and speculation around it seem to have peaked. At the same time, Goo
Riverhead Capital Management LLC boosted its stake in shares of Brown & Brown (NYSE:BRO) by 116.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,580 shares of the financial service